AI-Designed Vaccine Passes First Human Trial. Could It…

AI-Designed Vaccine Passes First Human Trial. Could It Help Stop Future Coronavirus Pandemics? TALMedora Health Desk What if scientists could design a vaccine not just for today's virus, but for future variants that don't even exist yet? That is the ambitious goal behind a new experimental vaccine that has become the first fully AI-designed vaccine to successfully complete human safety testing. Researchers say the vaccine could represent a major step toward developing broader protection against entire families of coronaviruses, including future threats similar to COVID-19 and SARS. The early findings also highlight how artificial intelligence may dramatically accelerate vaccine development in the years ahead. Traditional vaccines are typically developed to target a specific virus or variant. The challenge is that viruses constantly evolve. As seen during the COVID-19 pandemic, new variants can emerge rapidly, forcing scientists to update vaccines and public health strategies repeatedly. Researchers behind the new vaccine took a different approach. Instead of targeting a single virus, artificial intelligence was used to identify viral regions that remain relatively stable across multiple coronavirus strains. The goal was to create broader immune protection capable of recognizing both current and future coronavirus threats. The experimental vaccine, known as pEVAC-PS, was designed using computer-based modeling and artificial intelligence algorithms. Scientists used AI to analyze coronavirus structures and identify shared regions that are less likely to change as viruses mutate. This allowed researchers to create what they describe as a "u